newsMoffitt Cancer Center researchers have discovered that patients with desmoplastic…
12 January 2018 | By European Pharmaceutical Review
Moffitt Cancer Center researchers have discovered that patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed.